Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A.
about
Animal models of hemophiliaTherapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia AA review of current methods for assessing hemostasis in vivo and introduction to a potential alternative approach.Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria.Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoringTreatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment.Inhibitors in previously treated patients: a review of the literaturePatient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM.Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia AA randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A managementEfficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations.F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia A.Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy.Allometry of factor VIII and informed scaling of next-generation therapeutic proteins.Optimizing outcomes for patients with severe haemophilia A.Haemophilia A: meeting the needs of individual patients.Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.Back to the future: a recent history of haemophilia treatment.Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells.Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia ABayesian approach to the assessment of the population-specific risk of inhibitors in hemophilia A patients: a case study.A role for thrombin in the initiation of the immune response to therapeutic factor VIII.Key issues in inhibitor management in patients with haemophilia.Pediatric Dosing and Body Size in Biotherapeutics.Pharmacotherapy of haemophilia A.Non-thrombotic-, non-inhibitor-associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand's disease: a systematic review of prospective studies.Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies.Octocog alfa, antihaemophilic factor (recombinant), plasma/albumin free method (Advate®): a review of its use in the management of patients with haemophilia A.Octocog alfa (Advate®): a guide to its use in hemophilia A.Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method.Inhibitors - genetic and environmental factors.Individualizing prophylaxis in hemophilia: a review.Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq(®) ) in children with severe haemophilia A: efficacy, safety and pharmacokinetics.Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq(®) ) in adults with severe haemophilia A: efficacy and safety.Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study.Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A.Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series.
P2860
Q27012571-627F87D1-A381-4073-A0B2-065C51ADC648Q28075081-827EF89F-A647-4BBE-BB67-E0EB065908CDQ30442996-5A26F6CF-DBA9-4148-8998-2BCC6FF2F04CQ30958570-69B126B4-11B8-46DA-91C1-6586819D95CDQ31098999-453BBF47-869B-48A0-AAF6-15C93A2093BAQ33794432-735595B0-98F0-46DB-983B-CC9BBF9751E6Q34094037-2C286FE2-2839-4F89-98B2-565E2CC3B46FQ34777714-4625D60E-3582-43ED-8AB1-8E77EEBDCB9DQ35209354-B2E29100-803A-4553-BFDD-D96809B2CBFBQ36000862-C6D9F0D9-CCCA-4D0C-A7C0-F951991F16F6Q36369011-52F60A19-6D42-47A9-A069-42C4FA4CDE48Q36383257-43686177-18D1-4E6C-A6F5-158542856F3FQ36463399-D4C3D201-412E-4113-AE4F-FE983932299FQ36480548-B14B224D-A1D7-44D2-B741-4A54A2F934D6Q36536149-F5D7328F-CF95-4FA7-8AF7-D7104AECB54AQ36643868-6A4DAFDA-162E-4A88-9936-3D14B47D668EQ36912731-C06F4699-EAAC-449C-95F3-6A1DA281AA1CQ36932769-9EAEF380-B8A5-4B89-B2A8-77C25761E725Q37008132-5D0E750E-B215-4272-8DDC-A134D5A3B8E2Q37153245-93A8558E-2AB3-49CB-9A1C-3C570658B94EQ37176481-A2A22FF2-A323-4890-ACD4-8EE122DB4DDDQ37234113-F37D7DB4-A3F0-42DF-B939-82700A96566BQ37303186-092996AD-2220-48D3-84E9-FD08D4B65D1AQ37381565-086A6F43-A039-4AF4-B010-4ADDD771837FQ37428002-26097BB1-EBA0-45A2-B550-E44718C25291Q37602415-5A32849E-9FF7-4A18-859F-E8F5FDE031C6Q37666711-F0269453-0442-41C3-B896-DFF874E06B45Q37891089-D286FF9B-B3B9-4949-A985-C28B17AEBAD3Q37976470-04446FD4-9776-483E-9E58-DBAC9E27208BQ37984127-549EA3FA-AF0A-40AD-ADA9-640D1296122EQ38008021-FC578CA4-4F39-4AC5-BC9C-D206AB9A00B1Q38023600-6D64C450-D71A-450A-9B2C-DCACA4A17480Q38205211-BB72BB4B-A607-4D93-8514-A1DBF9FCAFB4Q38206856-60CBCE17-702A-4B82-9CDE-AE34AC8248ACQ38323857-91235A95-994F-4779-B7BE-A9E3431A6964Q38835294-09D67E6D-DE5A-41CF-B8B1-E74D9895C9F2Q38840145-FBF6514C-AF4F-4E1A-9E1D-60EB572E549AQ38888065-176D936F-05B3-4BF5-A8F8-C57C29A5D5A2Q38905322-12922F02-263C-4C50-AFB3-292F2A3ED0B1Q38958322-0A7915C3-484B-4790-B985-34B37B5B21DE
P2860
Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Clinical evaluation of an adva ...... d patients with haemophilia A.
@en
Clinical evaluation of an adva ...... d patients with haemophilia A.
@nl
type
label
Clinical evaluation of an adva ...... d patients with haemophilia A.
@en
Clinical evaluation of an adva ...... d patients with haemophilia A.
@nl
prefLabel
Clinical evaluation of an adva ...... d patients with haemophilia A.
@en
Clinical evaluation of an adva ...... d patients with haemophilia A.
@nl
P2093
P2860
P921
P1433
P1476
Clinical evaluation of an adva ...... d patients with haemophilia A.
@en
P2093
A D Retzios
A D Shapiro
B M Ewenstein
E Berntorp
M D Tarantino
M G Sensel
P C Schroth
P W Collins
P2860
P304
P356
10.1111/J.1365-2516.2004.00932.X
P577
2004-09-01T00:00:00Z